Please assess the completion status of the following clinical trial:

Trial Title: Phase II Dose-ranging Study of APD421 in PONV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria~1. Male or female patients ≥ 18 years of age~2. Ability and willingness to give written informed consent~3. Patients undergoing elective surgery under general anaesthesia requiring at least one overnight stay in hospital for either:~   1. Hysterectomy (any surgical technique)~  2. Cholecystectomy (any surgical technique)~  3. Other elective surgery requiring overnight admission to hospital and scheduled to last at least 1 hour from induction of anaesthesia~4. Patients with at least 2 of the following risk factors for PONV:~   1. Past history of PONV and/or motion sickness~  2. Habitual non-smoking status~  3. Female sex~  4. Expected to receive opioid analgesia post-operatively~5. American Society of Anesthesiologists (ASA) risk score I-III~6. Adequate cardiac, hepatic and renal function~   * QTc interval \< 500 ms~  * Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \< 5 x upper limit normal (ULN)~  * Bilirubin \< 3 x ULN~  * Creatinine \< 2 x ULN~7. Adequate haematological function~   * Haemoglobin ≥ 9 g/dL~  * White blood count ≥ 3.0 x 109/L~  * Platelet count ≥ 100 x 109/L~8. For females of child-bearing potential: ability and willingness to use a highly effective form of contraception (e.g., abstinence from sexual intercourse, surgical sterilisation (of subject or partner) or a double-barrier method of contraception such as either an intra-uterine device (IUD) or an occlusive cap with spermicide, in conjunction with partner's use of a condom) between the date of screening and at least 48 hours after administration of study drug.~Exclusion Criteria~1. Patients undergoing outpatient/day case surgery~2. Patients undergoing surgery where the patient is expected to remain ventilated for a period after surgery~3. Patients undergoing intra-thoracic, transplant or central nervous system surgery~4. Patients receiving a local anaesthetic/regional neuraxial (intrathecal or epidural) block~5. Patients who are expected to need a naso- or oral-gastric tube in situ after surgery is completed~6. Patients receiving the active ingredient of APD421 for any indication within the last 2 weeks~7. Patients who are allergic to the active ingredient or any of the excipients of APD421~8. Patients with a pre-existing vestibular disorder or history of dizziness~9. Patients with pre-existing nausea or vomiting in the 24 hours before surgery~10. Patients treated with regular anti-emetic therapy including corticosteroids~11. Patients being treated with medications which could induce torsades de pointes, including Class Ia antiarrhythmic agents such as quinidine, disopyramide, procainamide; Class III antiarrhythmic agents such as amiodarone and sotalol; and other medications such as bepridil, cisapride, thioridazine, methadone, IV erythromycin, IV vincamine, halofantrine, pentamidine, sparfloxacin~12. Patients being treated with levodopa~13. Patients who are pregnant or breast feeding~14. Patients with a history of alcohol abuse~15. Patients with pre-existing, clinically significant cardiac arrhythmia~16. Patients diagnosed with Parkinson's disease~17. Patients who have received anti-cancer chemotherapy in the previous 4 weeks~18. Patients with a history of epilepsy~19. Any other concurrent disease or illness that, in the opinion of the investigator makes the patient unsuitable for the study~20. Patients who have participated in a previous study within the last 28 days (French sites only: Patients who have participated in a previous study within the last 6 months, if required by national or local regulations)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Low dose APD421 (Type: EXPERIMENTAL): 1mg dose level
- Mid Dose APD421 (Type: EXPERIMENTAL): 5mg dose level
- High Dose APD421 (Type: EXPERIMENTAL): 20mg dose level

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete